These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29734838)

  • 1. Discordant prostate specific antigen test results despite WHO assay standardization.
    Boegemann M; Arsov C; Hadaschik B; Herkommer K; Imkamp F; Nofer JR; Gerß J; Albers P; Semjonow A
    Int J Biol Markers; 2018 Aug; 33(3):275-282. PubMed ID: 29734838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
    Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
    Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of assay methods for total and free PSA after WHO standardization.
    Foj L; Filella X; Alcover J; Augé JM; Escudero JM; Molina R
    Tumour Biol; 2014 Mar; 35(3):1867-73. PubMed ID: 24092573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.
    Kort SA; Martens F; Vanpoucke H; van Duijnhoven HL; Blankenstein MA
    Clin Chem; 2006 Aug; 52(8):1568-74. PubMed ID: 16762996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
    Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
    Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization of assay methods reduces variability of total PSA measurements: an Irish study.
    Forde JC; Marignol L; Blake O; McDermott T; Grainger R; Crowley VE; Lynch TH
    BJU Int; 2012 Sep; 110(5):644-50. PubMed ID: 22897326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
    Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
    BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
    Slev PR; La'ulu SL; Roberts WL
    Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
    Stephan C; Köpke T; Semjonow A; Lein M; Deger S; Schrader M; Miller K; Jung K
    Clin Chem Lab Med; 2009; 47(11):1325-31. PubMed ID: 19778292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
    Garrido MM; Marta JC; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
    In Vivo; 2021; 35(6):3431-3439. PubMed ID: 34697179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays.
    Fillée C; Tombal B; Philippe M
    Clin Chem Lab Med; 2010 Feb; 48(2):285-8. PubMed ID: 20001849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
    Stephan C; Cammann H; Meyer HA; Müller C; Deger S; Lein M; Jung K
    BJU Int; 2008 Sep; 102(7):799-805. PubMed ID: 18522632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006.
    Hillig T; Nielsen TK; Hansen SI; Nygaard AB; Sölétormos G
    Scand J Clin Lab Invest; 2017 Feb; 77(1):27-35. PubMed ID: 27762145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.